Please use this identifier to cite or link to this item: https://doi.org/10.1111/cen.14583
Title: The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review
Authors: Ng, Nicholas Beng Hui
Low, Yue Wey
Rajgor, Dimple Dayaram 
Low, Jia Ming 
Lim, Yvonne Yijuan
Loke, Kah Yin 
Lee, Yung Seng 
Keywords: Science & Technology
Life Sciences & Biomedicine
Endocrinology & Metabolism
diabetes mellitus
exenatide
glucagon-like peptide 1 receptor agonists
hyperphagia
liraglutide
obesity
Prader-Willi syndrome
PLASMA GHRELIN
HYPOTHALAMIC OBESITY
YOUNG-ADULTS
LIRAGLUTIDE
HYPERPHAGIA
INHIBITOR
APPETITE
CHILDREN
PATIENT
EXENATIDE
Issue Date: 26-Aug-2021
Publisher: WILEY
Citation: Ng, Nicholas Beng Hui, Low, Yue Wey, Rajgor, Dimple Dayaram, Low, Jia Ming, Lim, Yvonne Yijuan, Loke, Kah Yin, Lee, Yung Seng (2021-08-26). The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review. CLINICAL ENDOCRINOLOGY 96 (2) : 144-154. ScholarBank@NUS Repository. https://doi.org/10.1111/cen.14583
Abstract: Objective: The mainstay management of hyperphagia and obesity in Prader–Willi syndrome (PWS) relies on dietary restrictions, strict supervision and behavioural modifications, which can be stressful for the patient and caregiver. There is no established pharmacological strategy to manage this aspect of PWS. Theoretically, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP1-RA) used in patients with obesity and type 2 diabetes mellitus (T2DM) may be efficacious in weight and glycaemic control of PWS patients. We conducted a systematic review of the literature to summarize the evidence on the use of GLP1-RA in PWS patients. Design: Primary studies were searched in major databases using key concepts ‘Prader–Willi syndrome’ and ‘GLP1 receptor agonist’ and outcomes, ‘weight control OR glycaemic control OR appetite regulation’. Results: Ten studies included, summarizing GLP1-RA use in 23 PWS patients (age, 13–37 years), who had used either exenatide (n = 14) or liraglutide (n = 9) over a duration of 14 weeks to 4 years. Sixteen (70%) of these patients had T2DM. Ten patients experienced improvement in body mass index, ranging from 1.5 to 16.0 kg/m2, while improvement in HbA1c was seen in 19 of 23 cases, ranging between 0.3% and 7.5%. All five studies reporting appetite or satiety showed improvement in satiety levels. There were no reported serious side effects. Conclusions: GLP1-RA appears safe in PWS patients and may have potential benefits for weight, glycaemic and appetite control. Nonetheless, we also highlight a significant gap in the literature on the lack of well-designed studies in this area, which limits the recommendation of GLP1-RA use in PWS patients at present.
Source Title: CLINICAL ENDOCRINOLOGY
URI: https://scholarbank.nus.edu.sg/handle/10635/216305
ISSN: 03000664
13652265
DOI: 10.1111/cen.14583
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome A systematic review.pdfPublished version757.99 kBAdobe PDF

CLOSED

None

SCOPUSTM   
Citations

3
checked on Jan 26, 2023

Page view(s)

73
checked on Jan 26, 2023

Download(s)

1
checked on Jan 26, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.